Discovery and Role of a Novel Eicosanoid Family in Breast Cancer
Abstract
There is strong evidence for the induction of the pro-inflammatory enzymes 5-lipoxygenase (5-LOX) and cyclooxygenase-2 (COX-2) in many types of cancer, including breast cancer. Up regulation of both enzymes is associated with promoting tumor igenesis and a negative prognosis of the disease. The 5-LOX (leukotriene) and COX-2 (prostaglandin) pathways have traditionally been viewed as independent biosynthetic routes to eicosanoid lipid hormones, yet recent enzy-mological analyses establish that the 5-LOX product, 5-HETE, is an excellent COX-2 substrate, forming a novel double endoperoxide product that has the potential to evolve into a novel family of biomediators. We have used LC-MS and NMR to identify two cellular metabolites that are derived from the novel di-endoperoxide product. Formation of the metabolites is blocked by presence of the COX-2 inhibitor indomethacin. Detection of these products is a major step forward in establishing a potential novel eicosanoid-forming pathway resulting from the cross-over of the leukotriene and prostaglandin pathways in breast cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2009
- Accession Number
- ADA511854
Entities
People
- Claus M Schneider
Organizations
- Vanderbilt University Medical Center